Victor G Vogel

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. pmc Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene
    Victor G Vogel
    The University of Pittsburgh Cancer Institute, Magee Womens Hospital, 300 Halket Street, Pittsburgh, PA 15213, USA
    Clin Interv Aging 3:601-9. 2008
  2. ncbi request reprint Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
    Victor G Vogel
    Magee Womens Hospital, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 3221, USA
    JAMA 295:2727-41. 2006
  3. ncbi request reprint Raloxifene: a selective estrogen receptor modulator for reducing the risk of invasive breast cancer in postmenopausal women
    Victor G Vogel
    UPMC Cancer Center Magee Women s Hospital, 300 Halket Street, Room 3524, Pittsburgh, PA 15213, USA
    Womens Health (Lond Engl) 3:139-53. 2007
  4. pmc The NSABP Study of Tamoxifen and Raloxifene (STAR) trial
    Victor G Vogel
    University of Pittsburgh Cancer Institute, Magee Womens Hospital, Pittsburgh, PA 15213 3180, USA
    Expert Rev Anticancer Ther 9:51-60. 2009
  5. doi request reprint Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer
    Victor G Vogel
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Menopause 15:782-9. 2008
  6. ncbi request reprint Chemoprevention strategies 2006
    Victor G Vogel
    Magee Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213 3180, USA
    Curr Treat Options Oncol 8:74-88. 2007
  7. ncbi request reprint Identifying and screening patients at risk of second cancers
    Victor G Vogel
    Magee Womens Hospital, 300 Halket Street, Pittsburgh, PA 15213 3180, USA
    Cancer Epidemiol Biomarkers Prev 15:2027-32. 2006
  8. pmc Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer
    Victor G Vogel
    NSABP, Pittsburgh, PA 15212, USA
    Cancer Prev Res (Phila) 3:696-706. 2010
  9. pmc Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial
    Patricia A Ganz
    National Surgical Adjuvant Breast and Bowel Project Operations Center NSABP, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
    J Clin Oncol 29:1110-6. 2011
  10. doi request reprint Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR)
    Carolyn D Runowicz
    National Surgical Adjuvant Breast and Bowel Project, National Cancer Institute, Pittsburgh, PA, USA
    Am J Obstet Gynecol 205:535.e1-5. 2011

Detail Information

Publications59

  1. pmc Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene
    Victor G Vogel
    The University of Pittsburgh Cancer Institute, Magee Womens Hospital, 300 Halket Street, Pittsburgh, PA 15213, USA
    Clin Interv Aging 3:601-9. 2008
    ..Millions of postmenopausal women could derive net benefit from raloxifene through reduced rates of fracture and invasive breast cancer...
  2. ncbi request reprint Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
    Victor G Vogel
    Magee Womens Hospital, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 3221, USA
    JAMA 295:2727-41. 2006
    ..Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis...
  3. ncbi request reprint Raloxifene: a selective estrogen receptor modulator for reducing the risk of invasive breast cancer in postmenopausal women
    Victor G Vogel
    UPMC Cancer Center Magee Women s Hospital, 300 Halket Street, Room 3524, Pittsburgh, PA 15213, USA
    Womens Health (Lond Engl) 3:139-53. 2007
    ..The potential market for a compound shown to reduce the risk of breast cancer in postmenopausal women who are at increased risk for breast cancer is more than 10 million women in the USA alone...
  4. pmc The NSABP Study of Tamoxifen and Raloxifene (STAR) trial
    Victor G Vogel
    University of Pittsburgh Cancer Institute, Magee Womens Hospital, Pittsburgh, PA 15213 3180, USA
    Expert Rev Anticancer Ther 9:51-60. 2009
    ..The risk of other cancers, fractures, ischemic heart disease and stroke is similar for both drugs...
  5. doi request reprint Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer
    Victor G Vogel
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Menopause 15:782-9. 2008
    ..As many as 10 million women in the United States are at increased risk, and clinicians are obligated to identify these women and manage their risk appropriately...
  6. ncbi request reprint Chemoprevention strategies 2006
    Victor G Vogel
    Magee Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213 3180, USA
    Curr Treat Options Oncol 8:74-88. 2007
    ....
  7. ncbi request reprint Identifying and screening patients at risk of second cancers
    Victor G Vogel
    Magee Womens Hospital, 300 Halket Street, Pittsburgh, PA 15213 3180, USA
    Cancer Epidemiol Biomarkers Prev 15:2027-32. 2006
    ..Some of the cancers also incur a risk for a second malignancy at another anatomic site. In addition, there are well-described clinical genetic syndromes that, as unique clinical entities, predispose to second malignant tumors...
  8. pmc Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer
    Victor G Vogel
    NSABP, Pittsburgh, PA 15212, USA
    Cancer Prev Res (Phila) 3:696-706. 2010
    ..These results have important public health implications and clarify that both raloxifene and tamoxifen are good preventive choices for postmenopausal women with elevated risk for breast cancer...
  9. pmc Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial
    Patricia A Ganz
    National Surgical Adjuvant Breast and Bowel Project Operations Center NSABP, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
    J Clin Oncol 29:1110-6. 2011
    ..The National Surgical Adjuvant Breast and Bowel Project B-30 trial included menstrual history (MH) and quality-of-life (QOL) studies to compare treatments on these outcomes...
  10. doi request reprint Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR)
    Carolyn D Runowicz
    National Surgical Adjuvant Breast and Bowel Project, National Cancer Institute, Pittsburgh, PA, USA
    Am J Obstet Gynecol 205:535.e1-5. 2011
    ..This study reports the gynecologic conditions in postmenopausal women (intact uterus on enrollment) in the National Surgical Adjuvant Breast and Bowel Project (NSABP) study of tamoxifen and raloxifene (STAR)/P-2 trial...
  11. pmc Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer
    Catherine M Bender
    University of Pittsburgh School of Nursing, Pittsburgh, PA 15261, USA
    Menopause 14:995-8. 2007
    ..We hypothesized, therefore, that anastrozole would have a more profound effect on cognitive function than tamoxifen, a mixed estrogen agonist/antagonist...
  12. pmc What do perceived cognitive problems reflect?
    Catherine M Bender
    University of Pittsburgh School of Nursing, 3500 Victoria Street, Suite 415, Pittsburgh, PA 15261, USA
    J Support Oncol 6:238-42. 2008
    ..At a minimum, our results indicated that women's complaints of cognitive problems should prompt additional assessment to clarify the bases of the problem and initiate appropriate intervention...
  13. ncbi request reprint Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast can
    Elizabeth Tan-Chiu
    National Surgical Adjuvant Breast and Bowel Project NSABP, University of Pittsburgh, PA, USA
    J Clin Oncol 23:7811-9. 2005
    ..Trastuzumab is effective in treating human epidermal growth factor receptor 2 (HER2) -positive breast cancer, but it increases frequency of cardiac dysfunction (CD) when used with or after anthracyclines...
  14. ncbi request reprint Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1)
    Mary S Beattie
    Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, CA, USA
    J Natl Cancer Inst 98:110-5. 2006
    ..The purpose of this study was to determine whether sex hormone levels were associated with breast cancer risk and with response to tamoxifen in a high-risk population...
  15. doi request reprint Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials
    Victor G Vogel
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    J Natl Cancer Inst Monogr 2010:181-6. 2010
    ..51 per 1000 women assigned to tamoxifen and 2.11 per 1000 women assigned to raloxifene (risk ratio, 1.40; 95% confidence interval = 0.98 to 2.00)...
  16. doi request reprint Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
    Priya Rastogi
    University of Pittsburgh Cancer Institute Magee Womens Hospital, 300 Halket St, Room 3524, Pittsburgh, PA 15213, USA
    J Clin Oncol 26:778-85. 2008
    ..Protocol B-27 was designed to determine the effect of adding docetaxel (T) to preoperative AC on tumor response rates, DFS, and OS...
  17. ncbi request reprint Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
    Stephanie R Land
    National Surgical Adjuvant Breast and Bowel Project NSABP Operations and Biostatistical Centers, Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
    JAMA 295:2742-51. 2006
    ..Tamoxifen has been approved for breast cancer risk reduction in high-risk women, but how raloxifene compares with tamoxifen is unknown...
  18. ncbi request reprint National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ
    Victor G Vogel
    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 3180, USA
    Clin Cancer Res 9:495S-501S. 2003
    ..Outcomes will include both ipsilateral and contralateral new breast cancer and recurrences, as well as the occurrence of regional and distant disease. Enrollment will begin in early 2003...
  19. pmc Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial
    Susan L Greenspan
    Department of Medicine, University of Pittsburgh, 3471 Fifth Ave, Kaufmann Suite 1110, Pittsburgh, PA 15213, USA
    J Clin Oncol 26:2644-52. 2008
    ..Limited data are available on the efficacy of oral bisphosphonate therapy in breast cancer survivors. Our goal was to examine prevention of breast cancer-related bone loss in this cohort...
  20. ncbi request reprint Recognition and management of hereditary breast cancer syndromes
    Darcy L Thull
    Magee UPCI Breast Cancer Genetics Program, Magee Women s Hospital, Pittsburgh, Pennsylvania 15213, USA
    Oncologist 9:13-24. 2004
    ..Application of these principles can reduce morbidity in women with genetic predispositions to breast cancer...
  21. ncbi request reprint Recent results from clinical trials using SERMs to reduce the risk of breast cancer
    Victor G Vogel
    Department of Medicine, University of Pittsburgh Cancer Institute Magee Womens Hospital, 300 Halket Street, Room 3524, Pittsburgh, PA 15213, USA
    Ann N Y Acad Sci 1089:127-42. 2006
    ..Several ongoing and planned studies will evaluate the ability of aromatase inhibitors to reduce the risk of breast cancer in women at increased risk...
  22. ncbi request reprint The use of tamoxifen and raloxifene for the prevention of breast cancer
    D Lawrence Wickerham
    Operations Center, National Surgical Adjuvant Breast and Bowel Project, Allegheny Center, Pittsburgh, PA 15212, USA
    Recent Results Cancer Res 181:113-9. 2009
    ..51 vs 2.11 per 1,000; RR, 1.40; 95% CI, 0.98-2.00). There were 36 cases of uterine cancer with tamoxifen and 23 cases with raloxifene (RR, 0.63; 95% CI, 0.35-1.08)...
  23. ncbi request reprint The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial
    Victor G Vogel
    The National Surgical Adjuvant Breast and Bowel Project, NSABP Foundation Inc, Pittsburgh, PA, USA
    Clin Breast Cancer 3:153-9. 2002
    ..0% of black women, and 44.5% of Hispanic women. The trial will recruit a total of 22,000 postmenopausal women and is powered to demonstrate superior efficacy of either agent or their equivalence in reducing the incidence of primary breast..
  24. doi request reprint Urinary estrogen metabolites and breast cancer: a combined analysis of individual level data
    Cher M Dallal
    Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Int J Biol Markers 28:3-16. 2013
    ..This combined analysis of 5 published studies evaluates urinary 2-hydroxyestrone (2-OHE1), 16α-hydroxyestrone (16α-OHE1), and their ratio (2:16α-OHE1) in relation to breast cancer risk...
  25. doi request reprint Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women
    Alana G Hudson
    Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Cancer Epidemiol Biomarkers Prev 17:680-7. 2008
    ..These cross-sectional findings suggest that NSAID use may be associated with lower circulating estradiol levels, potentially representing one mechanism through which NSAIDs exert protective effects on breast cancer...
  26. doi request reprint Breast cancer risk management
    Jennifer G Reeder
    Division of Hematology Oncology, University of Pittsburgh Medical Center Cancer Pavilion, PA 15232, USA
    Clin Breast Cancer 7:833-40. 2007
    ..In this article, we will review the trials that led to the emergence of both tamoxifen and raloxifene as chemopreventive agents and will then offer a management strategy for breast cancer prevention in the primary care setting...
  27. ncbi request reprint Chemoprevention of breast cancer in postmenopausal women
    Brian A Geller
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Breast Dis 24:79-92. 2005
    ..At present, tamoxifen is the only FDA-approved agent for breast cancer risk reduction. Decisions regarding its use must remain highly individualized, involving careful consideration of its risks versus benefits...
  28. ncbi request reprint Preventing breast cancer in high-risk women, 2008
    Victor G Vogel
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pennsylvania, USA
    Oncology (Williston Park) 22:666-73; discussion 679, 682, 684. 2008
    ..Symptomatic side effects are comparable for the two drugs. Raloxifene is more appropriate than tamoxifen for reduction of breast cancer risk among postmenopausal women at increased risk for breast cancer...
  29. pmc Nucleotide excision repair deficiency is intrinsic in sporadic stage I breast cancer
    Jean J Latimer
    Department of Obstetrics, Gynecology and Reproductive Sciences, Magee Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 3180, USA
    Proc Natl Acad Sci U S A 107:21725-30. 2010
    ..In addition, reduced NER capacity, or reduced expression of NER genes, could provide a basis for the development of biomarkers for the identification of tumorigenic breast epithelium...
  30. ncbi request reprint Update on breast cancer prevention
    Priya Rastogi
    Breast Cancer Prevention Program, Magee Women s Hospital University of Pittsburgh, Department of Medicine, Section of Hematology Oncology, School of Medicine, Pittsburgh, Pennsylvania, USA
    Oncology (Williston Park) 17:799-805; discussion 808-10, 813. 2003
    ..The Study of Tamoxifen and Raloxifene is designed to compare the efficacy of tamoxifen and raloxifene in reducing breast cancer risk. Aromatase inhibitors will also be studied in the setting of chemoprevention for breast cancer...
  31. ncbi request reprint Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs)
    Shelly S Lo
    Section of Hematology Oncology, Department of Medicine, Magee University of Pittsburgh Cancer Institute Breast Program, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Best Pract Res Clin Endocrinol Metab 18:97-111. 2004
    ..Prevention studies involving raloxifene and aromatase inhibitors are currently being conducted...
  32. ncbi request reprint Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
    ..We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer...
  33. ncbi request reprint Breast cancer-related lymphedema--what are the significant predictors and how they affect the severity of lymphedema?
    Atilla Soran
    Magee Womens Hospital, Pittsburgh, Pennsylvania 15213, USA
    Breast J 12:536-43. 2006
    ..9 kg/m(2) (SD 7.5) for patients with moderate/severe LE (p < 0.05). The results of this stratified case-control study demonstrated that the risk and severity of LE was statistically related to infection, BMI, and level of hand use...
  34. ncbi request reprint Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial
    Susan L Greenspan
    Department of Medicine, University of Pittsburgh, 3471 Fifth Avenue, Suite 1110, Pittsburgh, Pennsylvania 15213 3221, USA
    J Clin Endocrinol Metab 92:131-6. 2007
    ..Few data are available on the safety and efficacy of once-weekly oral bisphosphonate therapy in breast cancer survivors...
  35. ncbi request reprint Cognitive impairment associated with adjuvant therapy in breast cancer
    Catherine M Bender
    University of Pittsburgh School of Nursing, Victoria Building, Suite 415, Pittsburgh, PA 15261, USA
    Psychooncology 15:422-30. 2006
    ..In conclusion, adjuvant chemotherapy in women with breast cancer can be associated with deteriorations in memory and this may persist over time. The addition of tamoxifen may lead to more widespread memory deficits...
  36. ncbi request reprint Breast cancer risk factors and mammographic breast density in women over age 70
    Francesmary Modugno
    Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA
    Breast Cancer Res Treat 97:157-66. 2006
    ..Breast density is a strong risk factor for breast cancer, but little is known about factors associated with breast density in women over 70...
  37. ncbi request reprint Prognostic factors for breast cancer and their use in the clinical setting
    Avina Kapoor
    University of Pittsburgh School of Medicine, Department of Medicine, Magee Womens Hospital, 300 Halket Street, Room 3524, Pittsburgh, PA 15213 3180, USA
    Expert Rev Anticancer Ther 5:269-81. 2005
    ..This review focuses on the clinical, pathologic, molecular and genetic prognostic tools available for use in patients with breast cancer, and their impact on clinical decisions and treatment selection...
  38. pmc Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer
    Chungyeul Kim
    National Surgical Adjuvant Breast and Bowel Project, Division of Pathology, 1307 Federal St, Pittsburgh, PA 15212, USA
    J Clin Oncol 29:4160-7. 2011
    ..We used gene expression profiling and ER protein assays to help elucidate molecular mechanism(s) responsible for tamoxifen resistance in breast tumors...
  39. ncbi request reprint Management of the high-risk patient
    Victor G Vogel
    University of Pittsburgh, Department of Medicine, 3550 Terrace Street, Scaife 1218, Pittsburgh PA 15261, USA
    Surg Clin North Am 83:733-51. 2003
    ....
  40. ncbi request reprint Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program
    James N Atkins
    National Surgical Adjuvant Breast and Bowel Project, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15212, USA
    Clin Colorectal Cancer 5:181-7. 2005
    ..In this study, these drugs were used in combination as first-line therapy in a group of patients with metastatic colorectal cancer...
  41. pmc Urinary estrogen metabolites in women at high risk for breast cancer
    Annie Im
    Magee UPCI Breast Cancer Prevention Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Carcinogenesis 30:1532-5. 2009
    ....
  42. ncbi request reprint Atypia in the assessment of breast cancer risk: implications for management
    Victor G Vogel
    University of Pittsburgh, Cancer Institute Magee Womens Hospital, Pittsburgh, Pennsylvania 15213 3180, USA
    Diagn Cytopathol 30:151-7. 2004
    ..The procedure opens the possibility of repeatable tracking of breast cytology over time, but its role as a risk assessment tool remains to be fully defined...
  43. pmc Haploinsufficiency for BRCA1 is associated with normal levels of DNA nucleotide excision repair in breast tissue and blood lymphocytes
    Jean J Latimer
    Department of Obstetrics, Gynecology and Reproductive Sciences, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
    BMC Med Genet 6:26. 2005
    ....
  44. ncbi request reprint Breast cancer prevention
    Jennifer G Reeder
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Cancer Treat Res 141:149-64. 2008
  45. ncbi request reprint Preventing hormone-dependent breast cancer in high-risk women
    Victor G Vogel
    J Natl Cancer Inst 95:91-3. 2003
  46. ncbi request reprint Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
    Victor G Vogel
    J Natl Cancer Inst 94:1504. 2002
  47. ncbi request reprint American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition
    Rowan T Chlebowski
    Health Services Research Department, American Society of Clinical Oncology, 1900 Duke Street, Suite 200, Alexandria, VA 22314, USA
    J Clin Oncol 20:3328-43. 2002
    ..To update an evidence-based technology assessment of chemoprevention strategies for breast cancer risk reduction. POTENTIAL INTERVENTIONS: Tamoxifen, raloxifene, aromatase inhibition, and fenretinide...
  48. ncbi request reprint Current comprehensive assessment and management of women at increased risk for breast cancer
    Alan B Hollingsworth
    Department of Surgery, Mercy Health Center, Mercy Women s Center, 4300 McAuley Blvd, Oklahoma City, OK 73120, USA
    Am J Surg 187:349-62. 2004
    ....
  49. ncbi request reprint Prevention in the balance
    Victor G Vogel
    Magee UPCI Breast Program, Magee Women s Hospital University of Pittsburgh Cancer Institute, Pennsylvania 15213, USA vvogel magee edu
    Oncologist 7:103-5. 2002
  50. ncbi request reprint Referral to cancer genetic counseling: are there stages of readiness?
    Suzanne M O'Neill
    Center for Medical Genetics, Evanston Northwestern Healthcare, 1000 Central Street, Evanston, IL 60201, USA
    Am J Med Genet C Semin Med Genet 142:221-31. 2006
    ..Theoretical frameworks are needed to study adherence to referral for cancer genetic counseling. Stage-based theories may have a role to play...
  51. ncbi request reprint Impact of sentinel lymph node biopsy on lymphedema following breast cancer treatment
    Atilla Soran
    Breast J 11:370-1. 2005
  52. ncbi request reprint Breast cancer risk assessment and risk reduction
    Lisa A Newman
    Breast Care Center, 1500 East Medical Center Drive, 3308 CGC, University of Michigan, Ann Arbor, MI 48109, USA
    Surg Clin North Am 87:307-16, vii-viii. 2007
    ..This article reviews available methods for assessing and reducing breast cancer risk...
  53. doi request reprint Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial
    Eleftherios P Mamounas
    Aultman Health Foundation, 2600 6th St, SW Canton, OH 44710, USA
    J Clin Oncol 26:1965-71. 2008
    ....
  54. ncbi request reprint Have we found the ultimate risk factor for breast cancer?
    Victor G Vogel
    J Clin Oncol 24:1791-4. 2006
  55. ncbi request reprint American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting
    James L Khatcheressian
    Virginia Commonwealth University Massey Cancer Center, Richmond, VA, USA
    J Clin Oncol 24:5091-7. 2006
    ..To update the 1999 American Society of Clinical Oncology (ASCO) guideline on breast cancer follow-up and management in the adjuvant setting...
  56. ncbi request reprint Ontology, oncology, and preventive economies: developing drugs for cancer prevention
    Victor G Vogel
    Clin Cancer Res 13:5227-8. 2007
  57. ncbi request reprint Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement
    Steven E Come
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 9:443S-6S. 2003
  58. ncbi request reprint Can statin therapy reduce the risk of breast cancer?
    Victor G Vogel
    J Clin Oncol 23:8553-5. 2005
  59. ncbi request reprint Why do we still use hormone replacement therapy? Why don't we use it more?
    Victor G Vogel
    J Clin Oncol 20:616-9. 2002